nasdaq:xtlb
|
13186929
|
Mar 23rd, 2024 12:00AM
|
XTL Biopharmaceuticals Ltd.
|
146
|
3.00
|
Open
|
|
Mar 23rd, 2024 01:04AM
|
Mar 23rd, 2024 07:36PM
|
XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB, TASE:XTLB.TA) is a clinical-stage biotech company focused on the development of pharmaceutical products for the treatment of autoimmune diseases including lupus.
The Company’s lead drug candidate, hCDR1, is a world-class clinical asset for the treatment of systemic lupus erythematosus (SLE). Treatments currently on the market for SLE are not effective enough for most patients and some have significant side effects. Robust clinical data on hCDR1 has been produced in three clinical trials with 400 patients and over 200 preclinical studies with data published in more than 40 peer reviewed scientific journals.
|
Open
|
|
Open
|
5 HaCharoshet St.
|
Raanana
|
|
IL
|
4365603
|
|
XTL Biopharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:xtlb
|
13186929
|
Mar 22nd, 2024 12:00AM
|
XTL Biopharmaceuticals Ltd.
|
146
|
3.00
|
Open
|
|
Mar 22nd, 2024 12:37AM
|
Mar 22nd, 2024 07:25PM
|
XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB, TASE:XTLB.TA) is a clinical-stage biotech company focused on the development of pharmaceutical products for the treatment of autoimmune diseases including lupus.
The Company’s lead drug candidate, hCDR1, is a world-class clinical asset for the treatment of systemic lupus erythematosus (SLE). Treatments currently on the market for SLE are not effective enough for most patients and some have significant side effects. Robust clinical data on hCDR1 has been produced in three clinical trials with 400 patients and over 200 preclinical studies with data published in more than 40 peer reviewed scientific journals.
|
Open
|
|
Open
|
5 HaCharoshet St.
|
Raanana
|
|
IL
|
4365603
|
|
XTL Biopharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:xtlb
|
13186929
|
Mar 21st, 2024 12:00AM
|
XTL Biopharmaceuticals Ltd.
|
146
|
3.00
|
Open
|
|
Mar 21st, 2024 06:09PM
|
Mar 21st, 2024 06:09PM
|
XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB, TASE:XTLB.TA) is a clinical-stage biotech company focused on the development of pharmaceutical products for the treatment of autoimmune diseases including lupus.
The Company’s lead drug candidate, hCDR1, is a world-class clinical asset for the treatment of systemic lupus erythematosus (SLE). Treatments currently on the market for SLE are not effective enough for most patients and some have significant side effects. Robust clinical data on hCDR1 has been produced in three clinical trials with 400 patients and over 200 preclinical studies with data published in more than 40 peer reviewed scientific journals.
|
Open
|
|
Open
|
5 HaCharoshet St.
|
Raanana
|
|
IL
|
4365603
|
|
XTL Biopharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:xtlb
|
13186929
|
Mar 20th, 2024 12:00AM
|
XTL Biopharmaceuticals Ltd.
|
146
|
3.00
|
Open
|
|
Mar 20th, 2024 02:46AM
|
Mar 20th, 2024 08:10PM
|
XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB, TASE:XTLB.TA) is a clinical-stage biotech company focused on the development of pharmaceutical products for the treatment of autoimmune diseases including lupus.
The Company’s lead drug candidate, hCDR1, is a world-class clinical asset for the treatment of systemic lupus erythematosus (SLE). Treatments currently on the market for SLE are not effective enough for most patients and some have significant side effects. Robust clinical data on hCDR1 has been produced in three clinical trials with 400 patients and over 200 preclinical studies with data published in more than 40 peer reviewed scientific journals.
|
Open
|
|
Open
|
5 HaCharoshet St.
|
Raanana
|
|
IL
|
4365603
|
|
XTL Biopharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:xtlb
|
13186929
|
Mar 19th, 2024 12:00AM
|
XTL Biopharmaceuticals Ltd.
|
145
|
3.00
|
Open
|
|
Mar 19th, 2024 01:55AM
|
Mar 19th, 2024 06:42PM
|
XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB, TASE:XTLB.TA) is a clinical-stage biotech company focused on the development of pharmaceutical products for the treatment of autoimmune diseases including lupus.
The Company’s lead drug candidate, hCDR1, is a world-class clinical asset for the treatment of systemic lupus erythematosus (SLE). Treatments currently on the market for SLE are not effective enough for most patients and some have significant side effects. Robust clinical data on hCDR1 has been produced in three clinical trials with 400 patients and over 200 preclinical studies with data published in more than 40 peer reviewed scientific journals.
|
Open
|
|
Open
|
5 HaCharoshet St.
|
Raanana
|
|
IL
|
4365603
|
|
XTL Biopharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:xtlb
|
13186929
|
Mar 18th, 2024 12:00AM
|
XTL Biopharmaceuticals Ltd.
|
145
|
3.00
|
Open
|
|
Mar 18th, 2024 12:57AM
|
Mar 18th, 2024 07:54PM
|
XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB, TASE:XTLB.TA) is a clinical-stage biotech company focused on the development of pharmaceutical products for the treatment of autoimmune diseases including lupus.
The Company’s lead drug candidate, hCDR1, is a world-class clinical asset for the treatment of systemic lupus erythematosus (SLE). Treatments currently on the market for SLE are not effective enough for most patients and some have significant side effects. Robust clinical data on hCDR1 has been produced in three clinical trials with 400 patients and over 200 preclinical studies with data published in more than 40 peer reviewed scientific journals.
|
Open
|
|
Open
|
5 HaCharoshet St.
|
Raanana
|
|
IL
|
4365603
|
|
XTL Biopharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:xtlb
|
13186929
|
Mar 16th, 2024 12:00AM
|
XTL Biopharmaceuticals Ltd.
|
145
|
3.00
|
Open
|
|
Mar 15th, 2024 11:58PM
|
Mar 16th, 2024 07:41PM
|
XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB, TASE:XTLB.TA) is a clinical-stage biotech company focused on the development of pharmaceutical products for the treatment of autoimmune diseases including lupus.
The Company’s lead drug candidate, hCDR1, is a world-class clinical asset for the treatment of systemic lupus erythematosus (SLE). Treatments currently on the market for SLE are not effective enough for most patients and some have significant side effects. Robust clinical data on hCDR1 has been produced in three clinical trials with 400 patients and over 200 preclinical studies with data published in more than 40 peer reviewed scientific journals.
|
Open
|
|
Open
|
5 HaCharoshet St.
|
Raanana
|
|
IL
|
4365603
|
|
XTL Biopharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:xtlb
|
13186929
|
Mar 15th, 2024 12:00AM
|
XTL Biopharmaceuticals Ltd.
|
144
|
3.00
|
Open
|
|
Mar 15th, 2024 07:37AM
|
Mar 15th, 2024 09:32AM
|
XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB, TASE:XTLB.TA) is a clinical-stage biotech company focused on the development of pharmaceutical products for the treatment of autoimmune diseases including lupus.
The Company’s lead drug candidate, hCDR1, is a world-class clinical asset for the treatment of systemic lupus erythematosus (SLE). Treatments currently on the market for SLE are not effective enough for most patients and some have significant side effects. Robust clinical data on hCDR1 has been produced in three clinical trials with 400 patients and over 200 preclinical studies with data published in more than 40 peer reviewed scientific journals.
|
Open
|
|
Open
|
5 HaCharoshet St.
|
Raanana
|
|
IL
|
4365603
|
|
XTL Biopharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:xtlb
|
13186929
|
Mar 14th, 2024 12:00AM
|
XTL Biopharmaceuticals Ltd.
|
144
|
3.00
|
Open
|
|
Mar 13th, 2024 11:57PM
|
Mar 14th, 2024 12:54PM
|
XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB, TASE:XTLB.TA) is a clinical-stage biotech company focused on the development of pharmaceutical products for the treatment of autoimmune diseases including lupus.
The Company’s lead drug candidate, hCDR1, is a world-class clinical asset for the treatment of systemic lupus erythematosus (SLE). Treatments currently on the market for SLE are not effective enough for most patients and some have significant side effects. Robust clinical data on hCDR1 has been produced in three clinical trials with 400 patients and over 200 preclinical studies with data published in more than 40 peer reviewed scientific journals.
|
Open
|
|
Open
|
5 HaCharoshet St.
|
Raanana
|
|
IL
|
4365603
|
|
XTL Biopharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:xtlb
|
13186929
|
Mar 13th, 2024 12:00AM
|
XTL Biopharmaceuticals Ltd.
|
144
|
3.00
|
Open
|
|
Mar 12th, 2024 11:51PM
|
Mar 13th, 2024 11:24AM
|
XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB, TASE:XTLB.TA) is a clinical-stage biotech company focused on the development of pharmaceutical products for the treatment of autoimmune diseases including lupus.
The Company’s lead drug candidate, hCDR1, is a world-class clinical asset for the treatment of systemic lupus erythematosus (SLE). Treatments currently on the market for SLE are not effective enough for most patients and some have significant side effects. Robust clinical data on hCDR1 has been produced in three clinical trials with 400 patients and over 200 preclinical studies with data published in more than 40 peer reviewed scientific journals.
|
Open
|
|
Open
|
5 HaCharoshet St.
|
Raanana
|
|
IL
|
4365603
|
|
XTL Biopharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|